ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer

VICTORIA, January 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as Chief Financial Officer.

Lisa Helbling brings over 30 years of experience in accounting, financing, and business development within the public markets and has a demonstrated ability to manage financial and operational challenges while governing a dynamic and growing business. Helbling previously served as the CFO at Anchor Ingredients, a specialty commodity company that provides end-to-end ingredient supply from farm origination, value added processing and distribution to human and pet food markets. In addition to sourcing commodities from ND and the U.S., the company imports products from 21 countries and exports products to 13 countries.

Helbling also held the CFO position at TMI Hospitality from December 2011 – December 2017. TMI develops and manages select service and extended stay hotels. The portfolio included 189 hotels across 27 states under 18 nationally recognized brands. TMI employed approximately 4,700 employees, 220 employees in the Fargo corporate office. Prior to working at TMI, Helbling worked at Otter Tail Corporation, from February 2002 – December 2011, a publicly traded (OTTR) electric utility with diversified operations in manufacturing, construction, transportation, health services, and food ingredient processing.

“I am delighted to join the executive team at ImmunoPrecise,” shared Lisa Helbling. “This is a very exciting time in their development, and I look forward to working with the talented and innovative team to help the Company achieve greater results for our employees and shareholders.”

As CFO, Helbling will report directly to Jennifer Bath, IPA’s President and CEO. “We are excited to welcome Lisa Helbling to ImmunoPrecise as our new CFO,” commented Jennifer Bath. “Lisa brings impressive financial, strategic and operational experience. She will be an enormous asset to ImmunoPrecise as we continue keeping pace in this rapidly growing industry and as ImmunoPrecise strives to become the premiere full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery.”

“On behalf of ImmunoPrecise’s Board of Directors, I want to thank Natasha Tsai for leading our finance team since the Company’s initial public offering”, added Jennifer Bath. “Her efforts and dedication have provided ImmunoPrecise with a strong foundation, enabling a seamless transition.”

The Company also announces that it has granted 415,000 stock options, of which 300,000 were granted to Helbing, 100,000 to Jason Orloske (VP Operations) and 15,000 to an employee.  The stock options are exercisable at $1.00 per share, subject to certain vesting requirements and expire five years from the date of grant.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ImmunoPrecise Antibodies Ltd.

For further information: For investor relations please contact: Frederick Chabot, Phone: 1-438-863-7071, Email:, Contact Financial Corp., 1450 – 701 West Georgia St., Vancouver, BC V7Y 1G5